keyword
MENU ▼
Read by QxMD icon Read
search

b cell lymphoma

keyword
https://www.readbyqxmd.com/read/29679112/post-treatment-positron-emission-tomography-computed-tomography-is-highly-predictive-of-outcome-in-plasmablastic-lymphoma
#1
Yassine Al Tabaa, Emmanuelle Tchernonog, Pierre Faurie, Anne Ségolène Cottereau, Hélène Monjanel, Antoine Bonnet, Steven Le Gouill, Emmanuel Gyan, Hervé Ghesquieres, Denis Mariano-Goulart, Guillaume Cartron
PURPOSE: Plasmablastic lymphoma (PBL) is a rare variant of diffuse large B cell lymphomas (DLBCL) clinically characterized by a poorer prognostic. Few clinical and imaging data are available and derived from pooled case reports and small series. The aim of the study was to evaluate the FDG avidity at baseline and the utility of 18-Fluorodeoxyglucose (FDG) positron-emission-tomography/computed-tomography (PET/CT) for staging and response assessment. METHODS: Patients with newly diagnosed PBL seen at Lymphoma Study Association centers during the period 2005-2015 were included if they underwent a PET/CT at staging and at the end of treatment (eotPET) and had received an anthracycline-based first line therapy...
April 20, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29678835/the-ezh2-inhibitor-tazemetostat-is-well-tolerated-in-a-phase-i-trial
#2
(no author information available yet)
Tazemetostat has antitumor activity in B-cell non-Hodgkin lymphoma and advanced solid tumors.
April 20, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29678657/development-and-evaluation-of-an-optimal-human-single-chain-variable-fragment-derived-bcma-targeted-car-t-cell-vector
#3
Eric L Smith, Mette Staehr, Reed Masakayan, Ishan J Tatake, Terence J Purdon, Xiuyan Wang, Pei Wang, Hong Liu, Yiyang Xu, Sarah C Garrett-Thomson, Steven C Almo, Isabelle Riviere, Cheng Liu, Renier J Brentjens
B cell maturation antigen (BCMA) has recently been identified as an important multiple myeloma (MM)-specific target for chimeric antigen receptor (CAR) T cell therapy. In CAR T cell therapy targeting CD19 for lymphoma, host immune anti-murine CAR responses limited the efficacy of repeat dosing and possibly long-term persistence. This clinically relevant concern can be addressed by generating a CAR incorporating a human single-chain variable fragment (scFv). We screened a human B cell-derived scFv phage display library and identified a panel of BCMA-specific clones from which human CARs were engineered...
March 28, 2018: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/29678441/acute-lymphoblastic-leukemia-lymphoma-of-the-oral-and-maxillofacial-region
#4
Celeste Sánchez-Romero, Hélder Antônio Rebelo Pontes, Flávia Sirotheau Corrêa Pontes, André Caroli Rocha, Román Carlos, Javier C Rendón, Oslei Paes de Almeida, Felipe Paiva Fonseca
OBJECTIVE: Our objective was to describe the clinicopathologic and immunohistochemical features of acute lymphoblastic leukemia/lymphoma (ALL/LBL) of the oral and maxillofacial region (OMF). STUDY DESIGN: Cases diagnosed as ALL/LBL of the OMF region were retrieved from the files of 2 Brazilian and 1 Guatemalan oral pathology services from 2005 to 2017. Microscopic and immunohistochemical features of each case were reviewed and fully described, and clinical data were retrieved from the pathology reports...
January 31, 2018: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/29676946/unclassifiable-b-cell-lymphoma-with-symptomatic-hyperleukocytosis-managed-with-leukapheresis
#5
Lakshmi Manogna Chintalacheruvu, Jayadev Manikkam Umakanthan, Teddi Hernandez, Bryan Teruya, Apar Kishor Ganti
No abstract text is available yet for this article.
April 20, 2018: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29676377/expect-the-unexpected-loss-of-surface-cd3-on-flow-cytometry-in-hepatosplenic-t-cell-lymphoma-an-eye-opener
#6
Richa Chauhan, Seema Tyagi, Sumeet Mirgh, Priyanka Mishra, Tulika Seth, Manoranjan Mahapatra, Haraprasad Pati, Renu Saxena
Hepatosplenic T-cell lymphoma (HSTCL) is a rare extranodal T-cell lymphoma that shows preferential sinusoidal infiltration of spleen and liver. It usually shows bright expression of surface CD3 (sCD3) with restriction for γδ-T cell receptors (TCR). We present a case of a 34-year-old male who presented with hepatosplenomegaly and B symptoms. His peripheral blood and bone marrow (BM) was involved by atypical lymphoid cells that were CD2+, CD7+, CD56+, cytoplasmic CD3+, and sCD3- on immunophenotyping by flow cytometry...
April 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29676376/an-unusual-presentation-of-large-b-cell-lymphoma-with-interferon-regulatory-factor-4-gene-rearrangement
#7
Anuj Verma, Sridhar Epari, Sumeet Gujral, Tanuja Shet
Rearrangements involving interferon regulatory factor 4 (IRF4) gene has been recently described in a subtype of diffuse large B-cell lymphoma (DLBCL). They occur in a typical clinical setting of a pediatric age group, predominantly with tonsillar mass, usually as a low-stage disease and with good response to chemotherapy. Histomorphologically, they show nodular/follicular architecture with diffuse strong immunopositivity for multiple myeloma oncogene 1. Here, the authors describe one such unusual case of large B-cell lymphoma with IRF4 gene rearrangement in a young child with the unusual location of inguinal region and detailed pathological (histological, immunohistochemical, and molecular) findings...
April 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29676363/lymphomatoid-granulomatosis-a-case-series-from-south-india
#8
Elanthenral Sigamani, Jagan Chandramohan, Sheila Nair, Geeta Chacko, Meera Thomas, Leni Grace Mathew, Susanne Pulimood, Marie Therese Manipadam
Context: Lymphomatoid granulomatosis (LYG) is a rare B-lymphoproliferative disorder characterised by an angiocentric and angiodestructive pattern along with Epstein - Barr virus (EBV) association. It is one of the diagnostic challenges in lymphoma pathology. Deregulation of EBV immune surveillance is one of the narrated hypotheses in the literature. Extrapulmonary manifestations are rare with LYG. Morphological grading is done based on the number of EBV-positive B cells, which is useful to strategize treatment protocol...
April 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29676358/frequency-distribution-and-immunomorphologic-characteristics-of-peripheral-t-cell-lymphoma-not-otherwise-specified-in-a-tertiary-care-center-in-southern-india
#9
Archana Lakshmanan, Deeksha Sikri, Sushama Patil, Ann Kurian, S Annapurneswari, Sheila Nair
Aims: In world literature, Peripheral T-cell lymphomas (PTCLs) constituted about 12% of non-Hodgkin's lymphomas (NHL) of which PTCL not otherwise specified (NOS) was the most common subtype. This study was undertaken to ascertain the frequency and to assess the morphologic and immunophenotypic characteristics of PTCL, NOS over a period of 5 years in a tertiary care referral center in Southern India. Materials and Methods: Slides and blocks of all PTCL, NOS were retrieved, and a detailed morphologic and immunophenotypic study using a wide panel of antibodies was done...
April 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29676233/chimeric-antigen-receptor-t-cell-based-immunotherapy-for-cancer
#10
Feng Li, Tengfei Zhang, Ling Cao, Yi Zhang
Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma...
April 19, 2018: Current Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/29675104/prognostic-value-of-bone-marrow-fdg-uptake-pattern-of-pet-ct-in-newly-diagnosed-diffuse-large-b-cell-lymphoma
#11
Yumei Chen, Mingge Zhou, Jianjun Liu, Gang Huang
Purpose: The value of 18 F-fluorodeoxyglucose positron emission tomography /computed tomography (18 F-FDG PET/CT) in assessing bone marrow involvement (BMI) of lymphoma remains controversial. The present study aims to evaluate the prognostic meaning of bone marrow FDG uptake pattern in PET/CT of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. Materials and Methods: 193 newly diagnosed DLBCL patients were retrospectively analyzed. All patients received 6-8 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29674676/comparative-high-resolution-transcriptome-sequencing-of-lymphoma-cell-lines-and-de-novo-lymphomas-reveals-cell-line-specific-pathway-dysregulation
#12
Leila Taher, Julia Beck, Wen Liu, Catrin Roolf, Jan T Soller, Barbara C Rütgen, Sabine E Hammer, Murali Chodisetti, Sina Sender, Katharina A Sterenczak, Georg Fuellen, Christian Junghanss, Bertram Brenig, Ingo Nolte, Ekkehard Schütz, Hugo Murua Escobar
In dogs as well as humans, lymphoma is one of the most common hematopoietic malignancies. Furthermore, due to its characteristics, canine lymphoma is recognized as a clinically relevant in vivo model to study the corresponding human disease. Immortalized cell lines are widely used as in vitro models to evaluate novel therapeutic agents and characterize their molecular mechanisms. However, it is known that long-term cultivation leads to clonal selection, genetic instability, and loss of the initial heterogenic character, limiting the usefulness of cell lines as preclinical models...
April 19, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29674626/prognostic-significances-of-overexpression-myc-and-or-bcl2-in-r-chop-treated-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis
#13
Lu Li, Yanyan Li, Ximei Que, Xue Gao, Qian Gao, Mingxing Yu, Kaili Ma, Yanfeng Xi, Tong Wang
Numerous studies have investigated the prognostic values of MYC and/or BCL2 protein overexpression in diffuse large B-cell lymphoma (DLBCL). However, the results still demonstrate discrepancies among different studies. We aimed to do a systematic review and meta-analysis on the relationships between overexpression MYC and/or BCL2 and DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This study followed the guidelines of PRISMA and Cochrane handbook. The hazard ratios (HRs) for overall survival (OS) were pooled to estimate the main effect size...
April 19, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29674440/lenalidomide-in-pretreated-mantle-cell-lymphoma-patients-an-italian-observational-multicenter-retrospective-study-in-daily-clinical-practice-the-lenamant-study
#14
Vittorio Stefoni, Cinzia Pellegrini, Alessandro Broccoli, Luca Baldini, Monica Tani, Emanuele Cencini, Amalia Figuera, Michela Ansuinelli, Elisa Bernocco, Maria Cantonetti, Maria Christina Cox, Filippo Ballerini, Chiara Rusconi, Carlo Visco, Luca Arcaini, Angelo Fama, Roberto Marasca, Stefano Volpetti, Alessia Castellino, Catello Califano, Marina Cavaliere, Guido Gini, Anna Marina Liberati, Gerardo Musuraca, Anna Lucania, Giuseppina Ricciuti, Lisa Argnani, Pier Luigi Zinzani
BACKGROUND: Mantle cell lymphoma (MCL) has the worst prognosis of B-cell subtypes owing to its aggressive clinical disease course and incurability with standard chemo-immunotherapy. Options for relapsed MCL are limited, although several single agents have been studied. Lenalidomide is available in Italy for patients with MCL based on a local disposition of the Italian Drug Agency. SUBJECTS, MATERIALS, AND METHODS: An observational retrospective study was conducted in 24 Italian hematology centers with the aim to improve information on effectiveness and safety of lenalidomide use in real practice...
April 19, 2018: Oncologist
https://www.readbyqxmd.com/read/29673902/la-ssb-chimeric-autoantibody-receptor-modified-nk92mi-cells-for-targeted-therapy-of-autoimmune-disease
#15
Huimin Meng, Xue Sun, Yanhui Song, Jianxuan Zou, Gangli An, Zeming Jin, Lin Yang
It has been long sought to specifically eliminate B-cell clones that generate autoreactive antibodies, while sparing the immune system when combating autoimmune disease. Although it was impossible to achieve this goal before, newly developed techniques have made it feasible today. Autoantibodies against La/SSB were involved in several autoimmune diseases. Here, we aimed to introduce La/SSB epitope-based chimeric autoantibody receptors (CAAR) into NK92MI cells enabled it to destroy the corresponding La/SSB-specific B cell receptor (BCR) -bearing lymphoma cells (LaA-BCR-Romas, LaA-BCR-Maver-1, and LaA-BCR-Jurkat cells)...
April 16, 2018: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/29673751/-primary-cutaneous-cd30-t-cell-lymphoproliferation-during-treatment-with-fingolimod-case-report-and-literature-review
#16
E Cesbron, J-B Monfort, C Giannesini, P Duriez, P Moguelet, P Senet, C Francès, A Barbaud, F Chasset
BACKGROUND: Fingolimod is an oral immunomodulator approved for relapsing-remitting multiple sclerosis. We report a case of a primary cutaneous CD30+ T-cell lymphoproliferation occurring 6 months after initiation of fingolimod. Based on a systematic literature review, the characteristics of these fingolimod-induced lymphoproliferative disorders are described. PATIENTS AND METHODS: A 56-year-old woman developed cutaneous indurated and ulcerated nodular lesions 6 months after starting fingolimod for active relapsing-remitting multiple sclerosis...
April 16, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29673048/emerging-diagnostic-tests-for-vitreoretinal-lymphoma
#17
REVIEW
Abby C Dawson, Keryn A Williams, Binoy Appukuttan, Justine R Smith
Vitreoretinal lymphoma, which most commonly is diffuse large B cell non-Hodgkin in type, is a rare cancer with high morbidity and high mortality. Making a tissue diagnosis of vitreoretinal lymphoma is a major challenge for clinicians due to biological and technical factors. Yet, the delay in start of treatment may have vision- and life- threatening consequences, and there is considerable interest in the application of molecular assays to improve the accuracy of the diagnostic process: detection of a clonal immunoglobulin heavy chain rearrangements in lymphoma cells by polymerase chain reaction; measurement of vitreous or aqueous interleukin-10 protein levels in ocular fluids; and identification of mutations in the myeloid differentiation primary response gene 88 in tumour cells...
April 19, 2018: Clinical & Experimental Ophthalmology
https://www.readbyqxmd.com/read/29672465/lactate-dehydrogenase-levels-and-18f-fdg-pet-ct-metrics-differentiate-between-mediastinal-hodgkin-s-lymphoma-and-primary-mediastinal-b-cell-lymphoma
#18
Rayan H M Alkhawtani, Walter Noordzij, Andor W J M Glaudemans, Rozemarijn S van Rijn, Hilde T van der Galiën, Hans Balink, Marcel Nijland, Hugo J A Adams, Gerwin Huls, Tom van Meerten, Thomas C Kwee
PURPOSE: This study aims to investigate whether clinical, laboratory, and fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT findings can discriminate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma (PMBCL). PATIENTS AND METHODS: This retrospective study included 56 patients (42 with mediastinal Hodgkin's lymphoma and 14 with PBMCL). Differences in clinical, laboratory, and F-FDG PET/CT metrics were assessed between Hodgkin's lymphoma and PMBCL...
April 18, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29672223/diagnosis-to-treatment-interval-is-an-important-clinical-factor-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-and-has-implication-for-bias-in-clinical-trials
#19
Matthew J Maurer, Hervé Ghesquières, Brian K Link, Jean-Philippe Jais, Thomas M Habermann, Carrie A Thompson, Corinne Haioun, Cristine Allmer, Patrick B Johnston, Richard Delarue, Ivana N Micallef, Frederic Peyrade, David J Inwards, Nicolas Ketterer, Umar Farooq, Olivier Fitoussi, William R Macon, Thierry J Molina, Sergei Syrbu, Andrew L Feldman, Susan L Slager, George J Weiner, Stephen M Ansell, James R Cerhan, Gilles A Salles, Thomas E Witzig, Hervé Tilly, Grzegorz S Nowakowski
Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the consent process and the inability to delay therapy for eligibility evaluation. We have examined the diagnosis-to-treatment interval (DTI) and its association with clinical factors and outcome in a clinic-based observational cohort of patients with DLBCL from the United States...
April 19, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29669863/continuous-signaling-of-cd79b-and-cd19-is-required-for-the-fitness-of-burkitt-lymphoma-b-cells
#20
Xiaocui He, Kathrin Kläsener, Joseena M Iype, Martin Becker, Palash C Maity, Marco Cavallari, Peter J Nielsen, Jianying Yang, Michael Reth
Expression of the B-cell antigen receptor (BCR) is essential not only for the development but also for the maintenance of mature B cells. Similarly, many B-cell lymphomas, including Burkitt lymphoma (BL), require continuous BCR signaling for their tumor growth. This growth is driven by immunoreceptor tyrosine-based activation motif (ITAM) and PI3 kinase (PI3K) signaling. Here, we employ CRISPR/Cas9 to delete BCR and B-cell co-receptor genes in the human BL cell line Ramos. We find that Ramos B cells require the expression of the BCR signaling component Igβ (CD79b), and the co-receptor CD19, for their fitness and competitive growth in culture...
April 18, 2018: EMBO Journal
keyword
keyword
35114
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"